Bristol Myers - Celgene CVRPreferred / convertible
13F holders, Q1 2025 (March 31)20holders
2new positions
2sold out
1famous investor
$0.14avg. 13F price*
At the end of Q1 2025, 20 institutions reported holding Bristol Myers - Celgene CVR in their 13F filings, unchanged from Q4 2024. 2 opened new positions and 2 sold out. The largest holders were Maven Securities LTD ($47K), Transcend Capital Advisors, LLC ($5K) and DAVENPORT & Co LLC ($4K). One famous investor held it Ken Griffin ( of Citadel Advisors's portfolio).
- Company
- Bristol Myers - Celgene CVR
- CUSIP
- 110122140
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $2K |
| Exits | 2 | $6.4M |
All 13F filers, Q4 2024 → Q1 2025: 48,279 shares bought and 509,065 shares sold, net −460,786 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 20 holders
| Maven Securities LTD | — | No change | 67,856 | $47K |
| Transcend Capital Advisors, LLC | — | Reduce -7.3% | 109,175 | $5K |
| DAVENPORT & Co LLC | — | No change | 83,970 | $4K |
| Bank of America Corp. | — | Add +0.3% | 51,818 | $3K |
| Citadel Advisors | — | New | 36,922 | $2K |
| Purkiss Capital Advisors LLC | — | No change | 26,450 | $1K |
| Two Sigma Securities, LLC | — | Reduce -1.8% | 25,679 | $1K |
| Fifth Third Bancorp | — | No change | 20,000 | $1K |
| Watts Gwilliam & Co., LLC | — | No change | 20,000 | $1K |
| Private Advisor Group, LLC | — | No change | 15,000 | $750 |
| UBS Group AG | — | Add +555.4% | 13,160 | $659 |
| Northwestern Mutual Wealth Management Co. | — | No change | 341 | $17 |
| Rothschild Investment LLC | — | No change | 166 | $8 |
| Morgan Stanley | — | No change | 119 | $6 |
| Oakworth Capital, Inc. | — | No change | 125 | $6 |
| JPMorgan Chase & Co. | — | No change | 23 | $1 |
| Wells Fargo & Company | — | No change | 28 | $1 |
| Whittier Trust Co. | — | New | 25 | $1 |
| Atlantic Edge Private Wealth Management, LLC | — | No change | 16 | $1 |
| Royal Bank of Canada | — | No change | 2,475 | $0 |
"% of holder's portfolio" is BRISTOL MYERS - CELGENE CVR's weight in each manager's 13F, not the share of Bristol Myers - Celgene CVR the manager owns.